Oak Ridge Investments LLC Lowers Stock Position in Guardant Health, Inc. $GH

Oak Ridge Investments LLC lowered its position in Guardant Health, Inc. (NASDAQ:GH) by 5.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,178 shares of the company’s stock after selling 743 shares during the period. Oak Ridge Investments LLC’s holdings in Guardant Health were worth $738,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Signaturefd LLC grew its position in Guardant Health by 50.5% during the second quarter. Signaturefd LLC now owns 635 shares of the company’s stock valued at $33,000 after buying an additional 213 shares during the period. American Century Companies Inc. grew its position in Guardant Health by 0.3% during the first quarter. American Century Companies Inc. now owns 104,206 shares of the company’s stock valued at $4,439,000 after buying an additional 282 shares during the period. IFP Advisors Inc grew its position in Guardant Health by 120.1% during the second quarter. IFP Advisors Inc now owns 612 shares of the company’s stock valued at $33,000 after buying an additional 334 shares during the period. HighTower Advisors LLC grew its position in Guardant Health by 0.9% during the first quarter. HighTower Advisors LLC now owns 51,107 shares of the company’s stock valued at $2,177,000 after buying an additional 469 shares during the period. Finally, PNC Financial Services Group Inc. grew its position in Guardant Health by 25.6% during the first quarter. PNC Financial Services Group Inc. now owns 2,638 shares of the company’s stock valued at $112,000 after buying an additional 537 shares during the period. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on GH shares. Mizuho increased their target price on shares of Guardant Health from $65.00 to $70.00 and gave the stock an “outperform” rating in a research report on Thursday, September 25th. JPMorgan Chase & Co. increased their target price on shares of Guardant Health from $60.00 to $70.00 and gave the stock an “overweight” rating in a research report on Thursday, September 25th. UBS Group increased their target price on shares of Guardant Health from $70.00 to $80.00 and gave the stock a “buy” rating in a research report on Thursday, September 25th. Cowen reiterated a “buy” rating on shares of Guardant Health in a research report on Thursday, September 25th. Finally, Canaccord Genuity Group increased their target price on shares of Guardant Health from $65.00 to $75.00 and gave the stock a “buy” rating in a research report on Friday, September 26th. Twenty-three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $65.86.

Guardant Health Trading Down 1.6%

GH stock opened at $64.22 on Monday. The firm has a 50 day moving average of $59.43 and a 200-day moving average of $50.21. Guardant Health, Inc. has a 12 month low of $20.14 and a 12 month high of $68.00. The firm has a market capitalization of $8.01 billion, a P/E ratio of -19.17 and a beta of 1.53.

Guardant Health (NASDAQ:GH) last released its quarterly earnings data on Wednesday, July 30th. The company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.08. The firm had revenue of $232.09 million during the quarter, compared to the consensus estimate of $211.19 million. During the same quarter last year, the business posted ($0.84) earnings per share. Guardant Health’s revenue was up 31.0% compared to the same quarter last year. Guardant Health has set its FY 2025 guidance at EPS. Sell-side analysts predict that Guardant Health, Inc. will post -2.9 EPS for the current year.

Insider Buying and Selling

In other news, Director Medina Manuel Hidalgo sold 2,165 shares of the firm’s stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $54.16, for a total value of $117,256.40. Following the completion of the transaction, the director directly owned 851 shares in the company, valued at approximately $46,090.16. This trade represents a 71.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Helmy Eltoukhy sold 300,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $59.45, for a total transaction of $17,835,000.00. Following the completion of the transaction, the chief executive officer owned 2,123,499 shares of the company’s stock, valued at $126,242,015.55. This trade represents a 12.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 302,691 shares of company stock valued at $17,981,965 over the last 90 days. 6.10% of the stock is owned by company insiders.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.